In a patient with LDL cholesterol 117 mg/dL, HDL cholesterol 31 mg/dL, and elevated triglycerides while taking rosuvastatin 10 mg daily, what additional medication should be added?

Add Ezetimibe to Rosuvastatin 10 mg

Your patient needs ezetimibe 10 mg added to the current rosuvastatin 10 mg regimen. This patient has three critical lipid abnormalities requiring immediate attention: LDL-C above goal, severely low HDL-C (31 mg/dL), and elevated triglycerides.

Primary Issue: LDL-C Not at Goal

With LDL-C of 117 mg/dL on rosuvastatin 10 mg, this patient has not achieved guideline-recommended targets. Without knowing the patient's cardiovascular risk category, I'll address the most common scenarios:

• If high cardiovascular risk (established CVD, diabetes with risk factors, or 10-year risk ≥20%): Target LDL-C <70 mg/dL 1
• If very high risk (established CVD with additional high-risk features): Target LDL-C <55 mg/dL 2, 3
• If moderate risk: Target LDL-C <100 mg/dL 1

The patient is not at goal in any of these scenarios.

Why Ezetimibe First

Algorithmic Approach:

1. First step when LDL-C not at goal on statin: Add ezetimibe 10 mg 1

   • Ezetimibe added to rosuvastatin 5-10 mg reduces LDL-C by an additional 21% 4
   • This would bring LDL-C from 117 mg/dL to approximately 92 mg/dL
   • Superior to doubling rosuvastatin dose (which only reduces LDL-C by 5.7% more) 4

2. Alternative considered but NOT recommended initially: Increasing rosuvastatin to 20 mg

   • Less effective than adding ezetimibe 4
   • Higher myopathy risk at 40 mg dose 5
   • The "rule of 6s" applies: each doubling of statin dose only reduces LDL-C by ~6% more

3. If still not at goal after rosuvastatin + ezetimibe: Consider PCSK9 inhibitor, bempedoic acid, or inclisiran 1

The HDL-C and Triglyceride Problem

Your patient's HDL-C of 31 mg/dL is severely low (goal >40 mg/dL in men, >50 mg/dL in women) 1. The elevated triglycerides compound this atherogenic dyslipidemia pattern.

Sequential Management Strategy:

Step 1 (Now): Add ezetimibe 10 mg

• Addresses the primary LDL-C problem
• Has modest beneficial effects on triglycerides 6
• Reassess lipids in 4-6 weeks 5

Step 2 (If triglycerides remain ≥150 mg/dL after ezetimibe):

• If triglycerides 150-499 mg/dL: Add icosapent ethyl 4 g/day 1

  • Preferred over fibrates for cardiovascular risk reduction
  • Safe with statins
  • Reduces cardiovascular events in high-risk patients 1

• If triglycerides ≥500 mg/dL: Consider fibrate (fenofibrate preferred over gemfibrozil) 7, 8, 9

  • Gemfibrozil should be avoided with rosuvastatin due to myopathy risk 5
  • Fenofibrate is safer with statins 10, 11
  • Keep rosuvastatin dose relatively low if combining with fibrate 7, 8

Step 3 (For persistent low HDL-C <40 mg/dL):

• Intensify lifestyle modifications (weight loss, exercise, Mediterranean diet) 1
• Consider fenofibrate or niacin after LDL-C optimization 7, 8
• Note: Niacin may worsen insulin resistance and is not recommended if diabetes risk is high 1

Critical Caveats

Do NOT add fibrate immediately because:

• LDL-C must be optimized first 7, 8, 9
• Combination of high-dose statin plus fibrate increases myopathy risk 7, 8
• If fibrate becomes necessary, use fenofibrate (NOT gemfibrozil) with rosuvastatin 5

Lifestyle modifications are mandatory:

• Reduce saturated fat to <7% of calories
• Cholesterol intake <200 mg/day
• Eliminate trans fats
• Increase fiber intake (≥10 g/day soluble fiber)
• Weight reduction if overweight
• Regular physical activity
• Alcohol moderation (triglycerides) 7, 8, 1

Reassessment timeline:

• Check lipid panel 4-6 weeks after adding ezetimibe 5
• If LDL-C still not at goal, escalate to PCSK9 inhibitor 1
• Address triglycerides and HDL-C only after LDL-C optimization

The combination of rosuvastatin + ezetimibe is highly effective and safe 4, 6, achieving LDL-C goals in significantly more patients than statin uptitration alone, with comparable adverse event rates.